|
| 神经损伤与功能重建尿激酶原、瑞替普酶和替奈普酶治疗急性缺血性卒中的研究进展 |
| Advances in the treatment of acute ischemic stroke with Prourokinase, Reteplase and Tenecteplase |
| 投稿时间：2025-03-26 修订日期：2025-03-26 |
| DOI： |
| 中文关键词: 急性缺血性卒中 静脉溶栓 尿激酶原 瑞替普酶 替奈普酶 |
| 英文关键词: Acute ischemic stroke Intravenous thrombolysis Prourokinase Reteplase Tenecteplase |
| 基金项目: |
|
| 摘要点击次数: 117 |
| 全文下载次数: 0 |
| 中文摘要: |
| 卒中是全球疾病、损伤和风险因素负担研究中的一大疾病,其中缺血性卒中(acute ischemic stroke,AIS)占比约达75%。静脉溶栓(intravenous thrombolysis,IVT)作为急性缺血性卒中最为有效的治疗手段之一,可在发病后第一时间开通闭塞血管、恢复血流,最大程度地降低AIS患者残疾或死亡的风险。近年来,众多具有较高安全性与独特疗效的IVT新型药物备受瞩目。本文将对尿激酶原、瑞替普酶、替奈普酶这三种用于IVT治疗的药物,从多中心研究现状、潜在作用机制等方面展开系统性总结,旨在为后续临床研究的推进,以及更多潜在机制的深入探索,提供坚实的理论支撑。 |
| 英文摘要: |
| Stroke is a major disease in the Global Burden of Disease, Injury, and Risk Factors study, with acute ischemic stroke (AIS) accounting for approximately 75% of the cases. Intravenous thrombolysis (IVT), as one of the most effective treatments for acute ischemic stroke, can open occluded blood vessels and restore blood flow at the first time after the onset of the disease, minimizing the risk of disability or death in patients with AIS. In recent years, numerous novel IVT drugs with high safety and unique efficacy have gained attention. In this paper, we will systematically summarize the current status of multicenter studies and potential mechanisms of action of Prourokinase, Reteplase, and Tenecteplase, which are three drugs used in IVT therapy, aiming to provide a solid theoretical support for the advancement of subsequent clinical studies and the in-depth exploration of more potential mechanisms. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|